Clinical trial
Prospective Phase 3 Multi-center 2-Year Placebo Controlled Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation 80 mg/Day in Alpha-1 Antitrypsin Deficiency With Moderate and Severe Airflow Limitation Followed by a 2-Year Open Label Extension
NCT04204252 is registered in ClinicalTrials.gov with Kamada, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Phase 3 Multi-center 2-Year Placebo Controlled Double Blind Study to Evaluate the Efficacy and Safety of Kamada-AAT for Inhalation 80 mg/Day in Alpha-1 Antitrypsin Deficiency With Moderate and Severe Airflow Limitation Followed by a 2-Year Open Label Extension
- Lead sponsor
- Kamada, Ltd.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 25, 2019
- Completion date
- February 27, 2026
- Enrollment
- 98 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.